Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M106,398Revenue (TTM) $M16,579Net Margin (%)34.2Altman Z-Score11.5
Enterprise Value $M103,795EPS (TTM) $2.2Operating Margin %43.9Piotroski F-Score7
P/E(ttm)18.1Beneish M-Score-3.3Pre-tax Margin (%)43.2Higher ROA y-yY
Price/Book17.210-y EBITDA Growth Rate %19.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales6.25-y EBITDA Growth Rate %17.3Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow15.9y-y EBITDA Growth Rate %19.8ROA % (ttm)42.9Higher Current Ratio y-yY
Dividend Yield %2.7PEG1.1ROE % (ttm)93.4Less Shares Outstanding y-yY
Payout Ratio %50.0Shares Outstanding M2,550ROIC % (ttm)151Gross Margin Increase y-yN

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

NVO is held by these investors:

NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVO :

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United May 03 2017 
    Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day Apr 17 2017 
    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Law Mar 08 2017 
    NVO Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Novo Nordisk Investors of March 13, 2017 Mar 06 2017 
    DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 05 2017 
    New Features: Individual Portfolio Tracker and Value Screens Tracker Mar 03 2017 
    NVO DEADLINE NOTICE: Rosen Law Firm Reminds Novo Nordisk A/S Investors of Important March 13 Deadlin Mar 02 2017 
    While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
    NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving No Feb 08 2017 

    More From Other Websites
    5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio May 24 2017
    AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk May 24 2017
    Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial May 23 2017
    Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices May 22 2017
    The 3 Best Obesity-Drug Stocks to Buy in 2017 May 19 2017
    Novelion CEO quits Novo Nordisk board due to NASH conflict May 16 2017
    The prices for life-saving diabetes medications have increased again May 15 2017
    Novo Nordisk Sees More Competition in U.S. Drug Prices May 10 2017
    Novo Nordisk CEO: Most growth coming from organic pipelin... May 10 2017
    Novo Nordisk A/S Jumps Over Its Lowered Bar May 04 2017
    Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y May 04 2017
    [$$] Novo Nordisk Struggles to Raise Prices May 03 2017
    [$$] Novo Nordisk Narrows Guidance as Earnings Beat Forecasts May 03 2017
    European stocks end lower, retreating from 20-month high ahead of Fed May 03 2017
    Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United... May 03 2017
    Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost May 03 2017
    Drugmaker Novo Nordisk nudges up full-year profit outlook after Q1 beat May 03 2017
    Novo Nordisk beats 1Q profit forecasts May 03 2017
    Novo's Legal Challenges Mount as States Query Insulin Prices May 03 2017
    Drugmaker Novo Nordisk beats Q1 operating profit forecast, nudges up FY outlook range May 03 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)